Share Email Print
cover

Proceedings Paper

Image guided 3D OCT for early diagnosis of carcinoma in situ of the bladder
Author(s): Hugang Ren; Ki Cheon Park; Rubin Pan; Kenneth Shroyer; Wayne Waltzer; Yingtian Pan
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Bladder carcinoma in situ (CIS) remains a clinical challenge. We compare the efficacies and potential limitations of surface imaging modalities, e.g., white light (WL), fluorescence (FC), blue-light imaging (BL) and 3D optical coherence tomography (3D OCT) for early diagnosis of bladder CIS. SV40T transgenic mice, which develop carcinoma in situ in about 8 to 20 weeks then high grade papillary tumor in the bladder, were employed as the rodent carcinogenesis model to closely mimic human bladder CIS. A total of 30 mice (i.e., SV40T mice blinded with its back strain Balb/c mice) were enrolled in the study, including 20 with CIS and 10 with normal or benign lesions of the bladder mucosa. Our results show that the low diagnostic sensitivities and specificities of WL, FC and BL for early CIS were significantly enhanced by quantitative 3D OCT to 95.0% and 90.0%, suggesting the value of image-guided 3D OCT for future clinical diagnosis of CIS in vivo.

Paper Details

Date Published: 30 January 2012
PDF: 7 pages
Proc. SPIE 8213, Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XVI, 82131C (30 January 2012); doi: 10.1117/12.909021
Show Author Affiliations
Hugang Ren, Stony Brook Univ. Medical Ctr. (United States)
Ki Cheon Park, Stony Brook Univ. Medical Ctr. (United States)
Rubin Pan, Stony Brook Univ. Medical Ctr. (United States)
Kenneth Shroyer, Stony Brook Univ. Medical Ctr. (United States)
Wayne Waltzer, Stony Brook Univ. Medical Ctr. (United States)
Yingtian Pan, Stony Brook Univ. Medical Ctr. (United States)


Published in SPIE Proceedings Vol. 8213:
Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XVI
Joseph A. Izatt; James G. Fujimoto; Valery V. Tuchin, Editor(s)

© SPIE. Terms of Use
Back to Top